BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?
作者信息
Jain Nitin, Jabbour Elias, Konopleva Marina
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Department of Leukemia, Montefiore Einstein Comprehensive Cancer Center, New York, NY.
出版信息
Haematologica. 2025 May 1;110(5):1053-1055. doi: 10.3324/haematol.2024.286816. Epub 2025 Feb 13.
Abstract
摘要
相似文献
1
BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?成人急性淋巴细胞白血病中的BCL2抑制作用：准备好进入黄金时代了吗？
Haematologica. 2025 May 1;110(5):1053-1055. doi: 10.3324/haematol.2024.286816. Epub 2025 Feb 13.
2
Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models.双BCL2/BCL-XL抑制剂AZD0466在急性淋巴细胞白血病临床前模型中的抗白血病疗效。
Blood Adv. 2025 Feb 11;9(3):473-487. doi: 10.1182/bloodadvances.2024013423.
3
DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition.双重特异性酪氨酸磷酸酶1A（DYRK1A）抑制导致MYC和细胞外信号调节激酶（ERK）激活，使KMT2A-R急性淋巴细胞白血病细胞对BCL2抑制敏感。
Leukemia. 2025 May;39(5):1078-1089. doi: 10.1038/s41375-025-02575-w. Epub 2025 Mar 27.
4
Vascular endothelial growth factor expression in acute myeloid leukemia: a biomarker ready for primetime?
Leuk Lymphoma. 2013 Jul;54(7):1345-6. doi: 10.3109/10428194.2013.765568. Epub 2013 Mar 5.
5
Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax.DNA 高甲基化导致 miR-182 表达降低，通过靶向 PBX3 和 BCL2 加速急性淋巴细胞白血病的发展：miR-182 启动子甲基化是低甲基化剂+BCL2 抑制剂 venetoclax 的预测标志物。
Clin Epigenetics. 2024 Mar 26;16(1):48. doi: 10.1186/s13148-024-01658-2.
6
Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia.miR-17~92 的差异表达将 BCL2 鉴定为 BCR-ABL 阳性 B 系急性淋巴细胞白血病的治疗靶点。
Leukemia. 2014 Mar;28(3):554-65. doi: 10.1038/leu.2013.361. Epub 2013 Nov 27.
7
De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis.小儿和年轻成人患者中出现的新发MYC和BCL2双打击B细胞前体急性淋巴细胞白血病（BCP-ALL）与预后不良相关。
Pediatr Hematol Oncol. 2015;32(8):535-47. doi: 10.3109/08880018.2015.1087611. Epub 2015 Nov 11.
8
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.基于网络的系统药理学揭示了LCK和BCL2信号通路的异质性以及T细胞急性淋巴细胞白血病的治疗敏感性。
Nat Cancer. 2021 Mar;2(3):284-299. doi: 10.1038/s43018-020-00167-4. Epub 2021 Jan 21.
9
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.维奈托克和纳武利尤单抗联合化疗治疗复发或难治性急性淋巴细胞白血病和淋巴母细胞淋巴瘤患者。
Cancer Discov. 2021 Jun;11(6):1440-1453. doi: 10.1158/2159-8290.CD-20-1465. Epub 2021 Feb 16.
10
CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.CXCR4 允许 T 细胞急性淋巴细胞白血病通过 CNS 浸润逃避 JAK1/2 和 BCL2 的抑制。
Leuk Lymphoma. 2021 May;62(5):1167-1177. doi: 10.1080/10428194.2021.1910684. Epub 2021 Apr 11.
本文引用的文献
1
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia.维奈克拉联合低强度化疗用于成人急性淋巴细胞白血病的治疗
Blood Adv. 2025 Feb 11;9(3):617-626. doi: 10.1182/bloodadvances.2024014405.
2
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.维奈托克联合一种源自儿科的方案用于治疗新诊断的费城染色体阴性成人急性淋巴细胞白血病。
Haematologica. 2025 May 1;110(5):1105-1114. doi: 10.3324/haematol.2024.286427. Epub 2024 Nov 7.
3
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.一项关于 mini-hyper-CVD 联合 venetoclax 治疗复发/难治性急性淋巴细胞白血病患者的 1/2 期研究。
Blood Adv. 2024 Feb 27;8(4):909-915. doi: 10.1182/bloodadvances.2023012231.
4
BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia.BH3分析确定了成年早期T细胞祖细胞急性淋巴细胞白血病患者对BCL-2的依赖性。
Blood Adv. 2023 Jun 27;7(12):2917-2923. doi: 10.1182/bloodadvances.2022007728.
5
Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response.儿科急性淋巴细胞白血病基因组图谱中的药物代谢型及其对治疗反应的影响。
Nat Med. 2023 Jan;29(1):170-179. doi: 10.1038/s41591-022-02112-7. Epub 2023 Jan 5.
6
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.维奈托克和纳武利尤单抗联合化疗治疗复发或难治性急性淋巴细胞白血病和淋巴母细胞淋巴瘤患者。
Cancer Discov. 2021 Jun;11(6):1440-1453. doi: 10.1158/2159-8290.CD-20-1465. Epub 2021 Feb 16.
7
Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.Bcl-2 是低倍体 B 系急性淋巴细胞白血病的治疗靶点。
Cancer Res. 2019 May 1;79(9):2339-2351. doi: 10.1158/0008-5472.CAN-18-0236. Epub 2019 Mar 12.
8
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.一项针对急性淋巴细胞白血病的大龄青少年和年轻成人的儿科治疗方案：CALGB 10403 研究结果。
Blood. 2019 Apr 4;133(14):1548-1559. doi: 10.1182/blood-2018-10-881961. Epub 2019 Jan 18.
9
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.体外药物反应分析检测耐药急性淋巴细胞白血病中的复发性敏感性模式。
Blood. 2017 Mar 16;129(11):e26-e37. doi: 10.1182/blood-2016-09-738070. Epub 2017 Jan 25.
10
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.费城样急性淋巴细胞白血病：成人中的一种高危亚型。
Blood. 2017 Feb 2;129(5):572-581. doi: 10.1182/blood-2016-07-726588. Epub 2016 Dec 5.
Zotero 插件